Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis.
暂无分享,去创建一个
Stefan Tenzer | Jörg Kuharev | Michael Maskos | Reinhard Zellner | Carolin Bier | S. Tenzer | H. Schild | Jörg Kuharev | W. Mann | M. Maskos | R. Stauber | S. Knauer | L. Treuel | D. Docter | T. Nawroth | R. Zellner | Lennart Treuel | Dominic Docter | Susanne Rosfa | Alexander Rekik | Jarinratn Sirirattanapan | Hansjörg Schild | Wolf Mann | Susanne Rosfa | A. Wlodarski | Alexander Rekik | Christoph Bantz | C. Bier | Jarinratn Sirirattanapan | Shirley K Knauer | Roland H Stauber | Alexandra Wlodarski | Christoph Bantz | Thomas Nawroth
[1] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[2] Sara Linse,et al. Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.
[3] M. Maskos,et al. Characterization of polymer nanoparticles by asymmetrical flow field flow fractionation (AF-FFF). , 2010, Journal of nanoscience and nanotechnology.
[4] Albert Duschl,et al. Time evolution of the nanoparticle protein corona. , 2010, ACS nano.
[5] Parag Aggarwal,et al. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.
[6] Benjamin Gilbert,et al. Extracellular Proteins Limit the Dispersal of Biogenic Nanoparticles , 2007, Science.
[7] Mauro Ferrari,et al. Nanogeometry: beyond drug delivery. , 2008, Nature nanotechnology.
[8] James S Murday,et al. Translational nanomedicine: status assessment and opportunities. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[9] Christoph Alexiou,et al. Targeting cancer cells: magnetic nanoparticles as drug carriers , 2006, European Biophysics Journal.
[10] M. Reilly,et al. HDL proteomics: pot of gold or Pandora's box? , 2007, The Journal of clinical investigation.
[11] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[12] Francesco Stellacci,et al. Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.
[13] Iseult Lynch,et al. Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.
[14] Yuval Golan,et al. The role of interparticle and external forces in nanoparticle assembly. , 2008, Nature materials.
[15] Marina A Dobrovolskaia,et al. Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.
[16] B. Adryan,et al. Analysis of differentially expressed proteins in oral squamous cell carcinoma by MALDI-TOF MS. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[17] W. Witke,et al. Gelsolin and diseases. , 2007, Sub-cellular biochemistry.
[18] U. Goldbourt,et al. Apolipoproteins and long-term prognosis in coronary heart disease patients. , 2009, American heart journal.
[19] Jerzy Leszczynski,et al. Bionanoscience: Nano meets bio at the interface. , 2010, Nature nanotechnology.
[20] W. Mann,et al. An otoprotective role for the apoptosis inhibitor protein survivin , 2010, Cell Death and Disease.
[21] Toshiro Hirai,et al. Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes , 2011, Particle and Fibre Toxicology.
[22] N Leigh Anderson,et al. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.
[23] Sara Linse,et al. Complete high‐density lipoproteins in nanoparticle corona , 2009, The FEBS journal.
[24] R. Aebersold,et al. A High-Confidence Human Plasma Proteome Reference Set with Estimated Concentrations in PeptideAtlas* , 2011, Molecular & Cellular Proteomics.
[25] P. Janmey,et al. Plasma gelsolin: function, prognostic value, and potential therapeutic use. , 2008, Current protein & peptide science.
[26] Scott E McNeil,et al. Nanoparticle therapeutics: a personal perspective. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[27] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[28] Reinhard Zellner,et al. The influence of surface composition of nanoparticles on their interactions with serum albumin. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.
[29] J. Klein. Probing the interactions of proteins and nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[30] Scott E McNeil,et al. Nanomaterial standards for efficacy and toxicity assessment. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[31] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[32] Wolfgang J Parak,et al. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. , 2009, Nature nanotechnology.
[33] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[34] S. Hanash,et al. BiomarkerDigger: A versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers , 2009, Proteomics.
[35] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[36] Parag Aggarwal,et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[37] Christine Pohl,et al. Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: Comparison with conventional monocultures , 2011, Particle and Fibre Toxicology.
[38] R. Müller,et al. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[39] D. Begley,et al. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain , 2010, Journal of drug targeting.
[40] Darren J. Martin,et al. Differential plasma protein binding to metal oxide nanoparticles , 2009, Nanotechnology.
[41] M. Gorenstein,et al. Absolute Quantification of Proteins by LCMSE , 2006, Molecular & Cellular Proteomics.
[42] Rainer H Müller,et al. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. , 2003, Journal of biomedical materials research. Part A.
[43] Iseult Lynch,et al. What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.
[44] T. Xia,et al. Potential health impact of nanoparticles. , 2009, Annual review of public health.
[45] Stefan Tenzer,et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. , 2009, Nature immunology.
[46] Sara Linse,et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[47] M. Mahmoudi,et al. Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.
[48] R. Marschalek,et al. Cell-based Analysis of Structure-Function Activity of Threonine Aspartase 1* , 2010, The Journal of Biological Chemistry.
[49] Subramaniam Pennathur,et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.
[50] Anil K Patri,et al. Method for analysis of nanoparticle hemolytic properties in vitro. , 2008, Nano letters.
[51] Jack F Douglas,et al. Interaction of gold nanoparticles with common human blood proteins. , 2010, ACS nano.
[52] Gilbert S Omenn,et al. Data management and data integration in the HUPO plasma proteome project. , 2011, Methods in molecular biology.
[53] M. Morandi,et al. Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.
[54] Mauro Ferrari,et al. Nanomedicine--challenge and perspectives. , 2009, Angewandte Chemie.
[55] Sara Linse,et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.
[56] Mark J DiNubile. Plasma gelsolin as a biomarker of inflammation , 2008, Arthritis research & therapy.
[57] Sara Linse,et al. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.
[58] Feng Zhang,et al. Quantitative analysis of the protein corona on FePt nanoparticles formed by transferrin binding , 2010, Journal of The Royal Society Interface.